Navigation Links
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Date:10/5/2007

BOSTON, Oct. 5 /PRNewswire/ -- Surface Logix, Inc. today announced the presentation of positive safety and efficacy data from its innovative Phase 1 repeat-dose clinical trial of its investigational drug candidate SLx-4090, a first-in-class enterocyte-specific microsomal triglyceride transfer protein (MTP) inhibitor being developed for the treatment of dyslipidemia (abnormal levels of lipids in the bloodstream). The data indicated not only that repeat- dosing at all dose levels of SLx-4090 was well tolerated, with no serious adverse events reported, but also that SLx-4090 significantly decreased plasma levels of both triglyceride and LDL-cholesterol compared to placebo. These data extend earlier findings previously reported from a single-dose study relating to the safety, tolerability and pharmacokinetic and pharmacodynamic profiles of SLx-4090. Results were presented at the 16th International Symposium on Drugs Affecting Lipid Metabolism being held October 4-7 in New York, NY.

"It is exciting that this novel compound continued to perform so well in this first repeat-dose study," said Dr. William Prince, Chief Development Officer of Surface Logix. "Consistent with our preclinical and Phase 1 single-dose results, no drug was detected in the plasma at doses up to 200 mg given three times daily for two weeks. This is particularly notable, as all other known MTP inhibitors have been shown to enter the systemic circulation and negatively impact standard measures of liver function. SLx-4090 was extremely well tolerated and adverse events were similar to those seen with placebo."

"Based on the results of this study, we have advanced SLx-4090 into a Phase 2a study, which will be completed shortly, and initial results are confirming the profile seen in both Phase 1 studies," said Jim Mahoney, President and Chief Executive Officer of Surface Logix. "We are also planning to start a Phase 2b study in patients with dyslipidemia in the middle of 2008. Based on
'/>"/>

SOURCE Surface Logix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2008)... Awareness and Bring Hope to Millions,of Children ...e/ -- 133 million children,across the globe are wi...disaster, civil war, and disease. SOS Children,s V...ek by calling attention to the needs of orphans,wo... to:, http://www.prnewswire.com/mnr/soschildrens...
(Date:10/9/2008)...s and Marketing Efforts to Accelerate ... PARK, Calif., Oct. 9 /- Evalve, Inc.... percutaneous repair of cardiac valves,has expand... appointment of,Sean Cleary as senior vice preside...ardson, as vice president of sales., "The additio...
(Date:10/9/2008)...titute, Navigenics, Affymetrix and,Microsoft team ... /- A consortium of health care,tech...a first-of-its-kind,research study to assess the b...ople who choose to receive such screenings to iden...iseases., Sponsored by Scripps Translational Scie...
(Date:10/8/2008)...re-USNewswire/ -- The facts are,overwhelming. Ever...b-Saharan Africa. More than 35,000,000 women, chil...ied of AIDS. The Foundation for Hospices,in Sub-Sa...eir families,find compassion and relief from suffe...ring initiative links African hospices and palliat...
Breaking Medicine Technology:Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 1Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 2Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 3Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 5Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 6Overuse of Opioids Barbiturates Boosts Chronic Migraine Risk 17140 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 2Migraines Frequency Influences Heart Attack Stroke Risk 17138 3Parents stricter with older kids to set example 3A game theory study 17136 1Parents stricter with older kids to set example 3A game theory study 17136 2
...h 20, 2007 /PRNewswire-FirstCall/ --,Alfacell Corp...l to,act as a potent payload in antibody conjugate...ion of the Handbook of Therapeutic,Antibodies. , I... Susanna,Rybak, Ph.D. summarizes preclinical resea... ONCONASE improves in a number of tumor,models, in...
...Enzyme Levels in Two Most Common Mutations, CRANBU...erapeutics, a biopharmaceutical company developing...al chaperones for the,treatment of a range of huma...resent the results of preclinical studies of,Plice...disease at,the of Medical Genetics (ACMG) annual m...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...reatment could help prevent future blood clots in ...mboembolism (VTE) affects approximately 2 million ...osis (blood clots common in the thigh and back) an...on in the lung). Despite progress in diagnosis and...
...ion for some patients with large liver tumors. The... //before using lasers to heat and destroy the tum...proves the overall survival of the patients. Radio...nduced thermotherapy (LITT) to heat tumors. The pr...
...on that can be fatal. It is defined as an obstruct... a blood clot, //which blocks a coronary artery. W...onary embolism, a new study shows a new treatment ...inister to patients than the current treatment. Ac...
...f the American Society of Therapeutic Radiology an...beam radiation may be what it takes to relieve pai...d to the bone. More than 160 hospitals and univers...were involved in a study of about 900 men and wome...
Other Medicine News:Health News:Extended Therapy for Blood Clots 2Health News:New Liver Tumor Treatment 2
...w XCD-SX910CR digital camera incorporates a Progre...excellent sensitivity (1280 (H) x 960 (V) SXGA. Wh...ask (commonly called a "Bayer filter") and outputs... converted to a color image on the computer. The c...
...661 is a monochrome " 1.3 Megapixel FireWire camer...s. Desgined to simplify real-time uncompressed vi...A661 provides uncompromising video and digital sti...-A661 is ideal for industrial inspection tasks inv...
...h acclaimed GT-CAPTURE digital camera photomicrogr...ers microscope such as Olympus, Leica, Nikon, and ...sferring images over the Internet easy and fast. F...ormance-proven Nikkor lens. The system records pho...
...0 is a superb stand-alone digital camera with netw...es from local or remote locations. Image acquisiti...amera operates independently or attaches directly ...o capture and transfer images. Sharing images in r...
Medicine Products: